Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4244096 | 0.82 | L3MBTL1 (0.57) | TRPV1CYP1A2CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL7783065 | 0.81 | ALDH1A1 (0.54) | RAB9AALDH1A1POLBL3MBTL1MAPT | |
| SCHEMBL8773803 | 0.80 | ALDH1A1 (0.53) | RAB9AALDH1A1POLBL3MBTL1MAPT | |
| SCHEMBL1041705 | 0.80 | TRPV1 (0.61) | TRPV1NPC1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL7545999 | 0.80 | TRPV1 (0.50) | TRPV1NPC1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1042846 | 0.80 | TRPV1 (0.61) | TRPV1NPC1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL5968384 | 0.78 | TRPV1 (0.59) | TRPV1NPC1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL7780979 | 0.77 | ALDH1A1 (0.52) | TRPV1ALDH1A1POLBL3MBTL1MAPT | |
| SCHEMBL7776086 | 0.77 | ALDH1A1 (0.41) | ALDH1A1POLBL3MBTL1MAPTP2RY1 | |
| SCHEMBL6180609 | 0.77 | FFAR4 (0.50) | CYP1A2CYP2C9CYP2C19SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020045634-A1 | Use of aryl-substituted pyrimidines as insecticidal and acaricidal agents | AMERICAN CYANAMID COMPANY | 2002-04-18 | — | — | US | claimed |
| US-6153619-A | Aryl-substituted pyrimidines as insecticidal and acaricidal agents | AMERICAN CYANAMID COMPANY (US) | 2000-11-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045634-A1 | Use of aryl-substituted pyrimidines as insecticidal and acaricidal agents | YBX1, YBX3, CYP1B1 | TRPV1 3410/4885NPC1 1752/4885CYP1A2 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.